Articles tagged "Highly-sensitized"

2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…
2016 American Transplant Congress
Anti-IL6R Therapy (Tocilizumab) Improves Long-Term Patient & Graft Survival in Patients with Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy.
J. Choi, A. Vo, M. Haas, D. Puliyanda, S. Louie, A. Peng, J. Kahwaji, R. Villicana, I. Kim, J. Mirocha, S. Jordan.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction:Extending the functionality of renal allografts is an essential goal of transplant medicine. HS patients (pts) are at increased risk for chronic ABMR (CABMR) due…
2016 American Transplant Congress
Incidence & Impact of De Novo DSA (dnDSA) Formation on Transplant Outcomes in HLA-Sensitized (HS) Patients Transplanted After IVG+Rituximab Desensitization (DES).
A. Vo,¹ J. Choi,¹ J. Kahwaji,¹ J. Mirocha,² A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Research Institute, Cedars-Sinai Medical Center, LA, CA.
Introduction: Highly-HLA sensitized patients are at risk for developing donor specific antibodies (DSA) & ABMR post-transplant (tx). However, incidence and risk of acute rejections (AR)…
2016 American Transplant Congress
Hospital Readmissions Following Incompatible Kidney Transplantation: A Multi-Center Study.
B. Orandi, E. King, X. Luo, S. Bae, B. Lonze, R. Montgomery, D. Segev.
Johns Hopkins, Baltimore.
Desensitization and incompatible live donor kidney transplantation (ILDKT) has improved survival vs. forgoing transplant or waiting for a compatible one. It is unknown if increased…
2016 American Transplant Congress
Anti-Angiotensin II Type 1 Receptor Antibody Reduction with Proteasome Inhibitor-Based Desensitization.
A. Girnita, E. Portwood, P. Brailey, S. Tremblay, R. Alloway, E. Woodle.
University of Cincinnati, Cincinnati.
Background. Desensitization results have largely focused on effects on anti-HLA antibody (HLA-Ab) and anti-ABO antibody levels. Anti-angiotensin II type 1 receptor antibody (AT1R-Ab) has recently…
2016 American Transplant Congress
Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.
E. Woodle, M. Pando Rigal, S. Tremblay, A. Girnita.
U of Cincinnati, Cincinnati; Mayo Clinic Scottsdale, Scottsdale.
Transplant (Transplant) rate is an optimal endpoint in desensitization (DS) trials in HLA sensitized Txp candidates, however, for waitlisted Txp candidates, wait time heterogeneity compromises…
2016 American Transplant Congress
Incidence of Viral Infections in HLA-Sensitized Patients (HS Pts) Desensitized with IVIG + Rituximab (DES) Compared to Non-HS Pts Receiving Standard Immunosuppression.
S. Jordan, J. Choi, B. Shin, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, M. Toyoda.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HS pts (PRA>50%, DSA+ at transplant) who are transplanted without DES represent a significant risk for antibody-mediated rejection. Prior to transplantation, HS pts require…
2015 American Transplant Congress
Kidney Paired Donation: National Activity and Perspectives
T. Dunn,¹ S. Fayek,² C. Marsh,³ P. Abt.⁴
¹Surgery, University of Minnesota, Minneapolis, MN; ²Surgery, Rush University Medical Center, Chicago, IL; ³Surgery, Scripps Health, La Jolla, CA; ⁴Surgery, University of Pennsylvania, Philadelphia, PA.
While utilization of Kidney Paired Donation (KPD) continues to increase, the potential is not fully realized. We surveyed kidney transplant (KTX) professionals to evaluate perceptions…
2015 American Transplant Congress
C1q Reactivity and IgG Subtypes After HLA Antibody Removal Therapy With Carfilzomib in Thoracic Transplant Recipients
A. Zeevi, M. Marrari, C. Bentlejewski, J. Pilewski, M. Morrell, J. McDyer, M. Shullo, J. Teuteberg, C. Bermudez, C. Ensor.
Univ of Pittsburgh, Pittsburgh.
Conventional therapies for antibody removal consisting of plasma exchange with IVIG and Rituximab are partially effective in desensitization protocols and for treatment of antibody mediated…
2015 American Transplant Congress
Measuring Affinity of Polyclonal HLA-Specific Antibodies in Highly Sensitised Cases Can Serve as an Additional Biomarker to Guide Direct Transplantation
S. Daga,^1,2 D. Lowe,⁶ R. Buchli,³ J. Collard,³ A. Mulder,⁸ C. McMurtrey,^3,4 H. Moyse,⁷ N. Evans,⁷ N. Krishnan,² W. Hildebrand,^3,4 F. Claas,⁸ D. Briggs,⁵ D. Zehnder,^1,2 D. Mithcell,¹ R. Higgins.^1,2
¹Clinical Sciences Research Laboratories, University of Warwick, Coventry, United Kingdom; ²Renal Unit, University Hospital, Coventry and Warwickshire NHS Trust, Coventry, United Kingdom; ³Pure Protein LLC, Oklahoma; ⁴University of Oklahoma Health Science Center, Oklahoma City; ⁵Department of Histocompatibility and Immunogenetics, NHS Blood and Transplant, Birmingham, United Kingdom; ⁶Department of Histocompatibility and Immunogenetics, Royal Liverpool University Hospital, Liverpool, United Kingdom; ⁷School of Engineering, University of Warwick, Coventry, United Kingdom; ⁸Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.
Significant numbers of patients on transplant waiting lists in the UK are sensitised (43%). Direct transplantation across these HLA-specific antibodies using risk stratification strategies are…